Diabetes shouldnt prevent you from donating, though
Diabetes Obes Metab 20:9981005 Jones RD, Jones HM, Rowland M, Gibson CR, Yates JW, Chien JY, Ring BJ, Adkison KK, Ku MS, He H, Vuppugalla R, Marathe P, Fischer V, Dutta S, Sinha VK, Bjornsson T, Lave T, Poulin P (2011) PhRMA CPCDC initiative on predictive models of human pharmacokinetics, part 2: comparative assessment of prediction methods of human volume of distribution
1 Key results for oral semaglutide 14 mg: HbA1c reduction: -1.5% (vs -0.1% with placebo) 80% achieved HbA1c below 7.0% (vs 34% with placebo) Weight loss: 2.3-2.6 kg more than placebo Injectable semaglutide: the SUSTAIN programme Across the SUSTAIN trials in type 2 diabetes: Semaglutide 0.5 mg: HbA1c reduction of approximately -1.5%, weight loss of 3-5 kg Semaglutide 1 mg: HbA1c reduction of approximately -1.5% to -1.8%, weight loss of 4.5-6.5 kg What explains the difference
Medicine that gets you
There are pharmacokinetic results of Semaglutide on aspects of absorption, distribution, elimination, metabolism, and excretion
Based on the STEP 1 clinical trial, patients lost approximately 2% of body weight per month for the first six months, slowing to about 1% per month thereafter, reaching an average of ~1516% total body weight loss by week 68
